AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
British biopharmaceutical company Vernalis Group Plc has revealed positive results from a study of its frovatriptan migraine treatment in menstrual migraine sufferers.
The Phase IV clinical trial showed that the recently-launched anti-migraine treatment was highly effective in preventing menstrually-associated migraine headaches. A total of 52% of patients involved in the placebo-controlled trial were completely headache-free during the six-day period when they took 5mg of frovatriptan daily, and 41% were headache-free at a daily dose of 2.5mg, compared to only 26% who took the placebo.
Vernalis will …